Form 4: Lexeo Therapeutics Director Brenda Cooperstone Reports Stock Option Grant

Director Brenda Cooperstone reports the acquisition of stock options in Lexeo Therapeutics.

Summary

• Brenda Cooperstone, a director of Lexeo Therapeutics, filed a Form 4 disclosing a transaction involving derivative securities.
• On June 25, 2024, Cooperstone acquired stock options for 18,000 shares of Lexeo Therapeutics common stock at an exercise price of $16.87.
• The options vest on the earlier of June 25, 2025, or the date of the Issuer's next annual stockholders meeting, contingent upon continuous service.
• Cooperstone also granted power of attorney to Jenny Robertson, Youjin Choi, Jessica McBride, Carole Rosenberg and James Reilly to execute and file Section 16 forms on her behalf.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. The grant of stock options is generally viewed positively as it aligns management interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in ways that increase shareholder value.

Key Dates